BACKGROUND: Acute myocardial infarction (AMI) is followed by post AMI cardiac remodelling, often leading to congestive heart failure. Homing of c-kit+ endothelial progenitor cells (EPC) has been thought to be the optimal source for regenerating infarcted myocardium. METHODS: Immune function of viable peripheral blood mononuclear cells (PBMC) was evaluated after co-culture with irradiated apoptotic PBMC (IA-PBMC) in vitro. Viable PBMC, IA-PBMC and culture supernatants (SN) thereof were obtained after 24 h. Reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay were utilized to quantify interleukin-8 (IL-8), vascular endothelial growth factor, matrix metalloproteinase-9 (MMP9) in PBMC, SN and SN exposed fibroblasts. Cell suspensions of viable- and IA-PBMC were infused in an experimental rat AMI model. Immunohistological analysis was performed to detect inflammatory and pro-angiogenic cells within 72 h post-infarction. Functional data and determination of infarction size were quantified by echocardiography and Elastica van Gieson staining. RESULTS: The IA-PBMC attenuated immune reactivity and resulted in secretion of pro-angiogenic IL-8 and MMP9 in vitro. Fibroblasts exposed to viable and IA-PBMC derived SN caused RNA increment of IL-8 and MMP9. AMI rats that were infused with IA-PBMC cell suspension evidenced enhanced homing of endothelial progenitor cells within 72 h as compared to control (medium alone, viable-PBMC). Echocardiography showed a significant reduction in infarction size and improvement in post AMI remodelling as evidenced by an attenuated loss of ejection fraction. CONCLUSION: These data indicate that infusion of IA-PBMC cell suspension in experimental AMI circumvented inflammation, caused preferential homing of regenerative EPC and replaced infarcted myocardium.
BACKGROUND: Acute myocardial infarction (AMI) is followed by post AMI cardiac remodelling, often leading to congestive heart failure. Homing of c-kit+ endothelial progenitor cells (EPC) has been thought to be the optimal source for regenerating infarcted myocardium. METHODS: Immune function of viable peripheral blood mononuclear cells (PBMC) was evaluated after co-culture with irradiated apoptotic PBMC (IA-PBMC) in vitro. Viable PBMC, IA-PBMC and culture supernatants (SN) thereof were obtained after 24 h. Reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay were utilized to quantify interleukin-8 (IL-8), vascular endothelial growth factor, matrix metalloproteinase-9 (MMP9) in PBMC, SN and SN exposed fibroblasts. Cell suspensions of viable- and IA-PBMC were infused in an experimental rat AMI model. Immunohistological analysis was performed to detect inflammatory and pro-angiogenic cells within 72 h post-infarction. Functional data and determination of infarction size were quantified by echocardiography and Elastica van Gieson staining. RESULTS: The IA-PBMC attenuated immune reactivity and resulted in secretion of pro-angiogenic IL-8 and MMP9 in vitro. Fibroblasts exposed to viable and IA-PBMC derived SN caused RNA increment of IL-8 and MMP9. AMI rats that were infused with IA-PBMC cell suspension evidenced enhanced homing of endothelial progenitor cells within 72 h as compared to control (medium alone, viable-PBMC). Echocardiography showed a significant reduction in infarction size and improvement in post AMI remodelling as evidenced by an attenuated loss of ejection fraction. CONCLUSION: These data indicate that infusion of IA-PBMC cell suspension in experimental AMI circumvented inflammation, caused preferential homing of regenerative EPC and replaced infarcted myocardium.
Authors: Alfred Gugerell; Dirk Sorgenfrey; Maria Laggner; Jürgen Raimann; Anja Peterbauer; Daniel Bormann; Susanne Suessner; Christian Gabriel; Bernhard Moser; Tobias Ostler; Michael Mildner; Hendrik J Ankersmit Journal: Blood Transfus Date: 2019-02-21 Impact factor: 3.443
Authors: Sonam Dilwali; Andrew Lysaght; Daniel Roberts; Fred G Barker; Michael J McKenna; Konstantina M Stankovic Journal: Otol Neurotol Date: 2013-06 Impact factor: 2.311
Authors: K Hoetzenecker; A Assinger; M Lichtenauer; M Mildner; T Schweiger; P Starlinger; A Jakab; E Berényi; N Pavo; M Zimmermann; C Gabriel; C Plass; M Gyöngyösi; I Volf; H J Ankersmit Journal: Basic Res Cardiol Date: 2012-08-17 Impact factor: 17.165
Authors: Michael Lichtenauer; Michael Mildner; Andrea Baumgartner; Matthias Hasun; Gregor Werba; Lucian Beer; Patrick Altmann; Georg Roth; Mariann Gyöngyösi; Bruno Karl Podesser; Hendrik Jan Ankersmit Journal: Basic Res Cardiol Date: 2011-03-17 Impact factor: 17.165
Authors: Michael Lichtenauer; Michael Mildner; Konrad Hoetzenecker; Matthias Zimmermann; Bruno Karl Podesser; Wolfgang Sipos; Ervin Berényi; Martin Dworschak; Erwin Tschachler; Mariann Gyöngyösi; Hendrik Jan Ankersmit Journal: Basic Res Cardiol Date: 2011-09-28 Impact factor: 17.165
Authors: Patrick Altmann; Michael Mildner; Thomas Haider; Denise Traxler; Lucian Beer; Robin Ristl; Bahar Golabi; Christian Gabriel; Fritz Leutmezer; Hendrik Jan Ankersmit Journal: F1000Res Date: 2014-06-19
Authors: Lucian Beer; Rudolf Seemann; Robin Ristl; Adolf Ellinger; Mohammad Mahdi Kasiri; Andreas Mitterbauer; Matthias Zimmermann; Christian Gabriel; Mariann Gyöngyösi; Walter Klepetko; Michael Mildner; Hendrik Jan Ankersmit Journal: BMC Genomics Date: 2014-09-25 Impact factor: 3.969
Authors: Michael Lichtenauer; Michael Mildner; Gregor Werba; Lucian Beer; Konrad Hoetzenecker; Andrea Baumgartner; Matthias Hasun; Stefanie Nickl; Andreas Mitterbauer; Matthias Zimmermann; Mariann Gyöngyösi; Bruno Karl Podesser; Walter Klepetko; Hendrik Jan Ankersmit Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240
Authors: Michael Mildner; Stefan Hacker; Thomas Haider; Maria Gschwandtner; Gregor Werba; Caterina Barresi; Matthias Zimmermann; Bahar Golabi; Erwin Tschachler; Hendrik Jan Ankersmit Journal: PLoS One Date: 2013-03-22 Impact factor: 3.240